| Followers | 1742 |
| Posts | 144060 |
| Boards Moderated | 3 |
| Alias Born | 09/11/2005 |
Friday, December 31, 2021 1:04:32 PM
Yea... I didn't see the huge day coming today... sold too soon, but still got a nice bottom bounce play out of it... I'm worried they will have some more bad NEWS and it will test the previous low... If it does, I'll be right back in...
Recent BBIO News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/27/2026 08:01:34 PM
- BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9 • GlobeNewswire Inc. • 05/27/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 08:26:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/18/2026 08:24:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:01:37 PM
- Wall Street's Cardiac Bet: Where Diagnostics Meet the Money • PR Newswire (US) • 05/12/2026 12:30:00 PM
- Wall Street's Cardiac Bet: Where Diagnostics Meet the Money • PR Newswire (Canada) • 05/12/2026 12:30:00 PM
- BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 • GlobeNewswire Inc. • 05/12/2026 11:30:00 AM
- Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure • GlobeNewswire Inc. • 05/11/2026 01:30:00 PM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/08/2026 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 01:01:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:31:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:02:53 PM
- BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates • GlobeNewswire Inc. • 05/07/2026 08:01:00 PM
- BridgeBio to Participate in May and June Investor Conferences • GlobeNewswire Inc. • 05/06/2026 08:01:00 PM
- BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil • GlobeNewswire Inc. • 05/06/2026 11:30:00 AM
- BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE • GlobeNewswire Inc. • 05/05/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:22:25 PM
- BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026 • GlobeNewswire Inc. • 05/04/2026 11:30:00 AM
- BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET • GlobeNewswire Inc. • 04/30/2026 11:30:00 AM
- BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White • GlobeNewswire Inc. • 04/28/2026 11:30:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/24/2026 08:26:28 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 08:25:54 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:25:16 PM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/22/2026 11:30:00 AM
